205 related articles for article (PubMed ID: 37127892)
1. In Situ Vaccination with Mitochondria-Targeting Immunogenic Death Inducer Elicits CD8
Wang Y; Wang W; Gu R; Chen J; Chen Q; Lin T; Wu J; Hu Y; Yuan A
Adv Sci (Weinh); 2023 Jul; 10(20):e2300286. PubMed ID: 37127892
[TBL] [Abstract][Full Text] [Related]
2. CD4
Xiao M; Xie L; Cao G; Lei S; Wang P; Wei Z; Luo Y; Fang J; Yang X; Huang Q; Xu L; Guo J; Wen S; Wang Z; Wu Q; Tang J; Wang L; Chen X; Chen C; Zhang Y; Yao W; Ye J; He R; Huang J; Ye L
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35580929
[TBL] [Abstract][Full Text] [Related]
3. Mitochondrial-targeted brequinar liposome boosted mitochondrial-related ferroptosis for promoting checkpoint blockade immunotherapy in bladder cancer.
Ding Q; Tang W; Li X; Ding Y; Chen X; Cao W; Wang X; Mo W; Su Z; Zhang Q; Guo H
J Control Release; 2023 Nov; 363():221-234. PubMed ID: 37717657
[TBL] [Abstract][Full Text] [Related]
4. Adding liposomal doxorubicin enhances the abscopal effect induced by radiation/αPD1 therapy depending on tumor cell mitochondrial DNA and cGAS/STING.
Wang L; Luo R; Onyshchenko K; Rao X; Wang M; Menz B; Gaedicke S; Grosu AL; Firat E; Niedermann G
J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37640480
[TBL] [Abstract][Full Text] [Related]
5. Manganese is critical for antitumor immune responses via cGAS-STING and improves the efficacy of clinical immunotherapy.
Lv M; Chen M; Zhang R; Zhang W; Wang C; Zhang Y; Wei X; Guan Y; Liu J; Feng K; Jing M; Wang X; Liu YC; Mei Q; Han W; Jiang Z
Cell Res; 2020 Nov; 30(11):966-979. PubMed ID: 32839553
[TBL] [Abstract][Full Text] [Related]
6. Endoplasmic Reticulum-Targeting AIE Photosensitizers to Boost Immunogenic Cell Death for Immunotherapy of Bladder Carcinoma.
Miao Z; Li J; Zeng S; Lv Y; Jia S; Ding D; Li W; Liu Q
ACS Appl Mater Interfaces; 2024 Jan; 16(1):245-260. PubMed ID: 38113527
[TBL] [Abstract][Full Text] [Related]
7. Nanomicelle protects the immune activation effects of Paclitaxel and sensitizes tumors to anti-PD-1 Immunotherapy.
Yang Q; Shi G; Chen X; Lin Y; Cheng L; Jiang Q; Yan X; Jiang M; Li Y; Zhang H; Wang H; Wang Y; Wang Q; Zhang Y; Liu Y; Su X; Dai L; Tang M; Li J; Zhang L; Qian Z; Yu D; Deng H
Theranostics; 2020; 10(18):8382-8399. PubMed ID: 32724476
[TBL] [Abstract][Full Text] [Related]
8. In situ vaccination with cowpea mosaic virus elicits systemic antitumor immunity and potentiates immune checkpoint blockade.
Mao C; Beiss V; Ho GW; Fields J; Steinmetz NF; Fiering S
J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36460333
[TBL] [Abstract][Full Text] [Related]
9. Stimuli-responsive nano vehicle enhances cancer immunotherapy by coordinating mitochondria-targeted immunogenic cell death and PD-L1 blockade.
Li Q; Chen C; Kong J; Li L; Li J; Huang Y
Acta Pharm Sin B; 2022 May; 12(5):2533-2549. PubMed ID: 35646521
[TBL] [Abstract][Full Text] [Related]
10. Genetically Edited Cascade Nanozymes for Cancer Immunotherapy.
Zhang J; Pan Y; Liu L; Xu Y; Zhao C; Liu W; Rao L
ACS Nano; 2024 May; 18(19):12295-12310. PubMed ID: 38695532
[TBL] [Abstract][Full Text] [Related]
11. In situ immunogenic clearance induced by a combination of photodynamic therapy and rho-kinase inhibition sensitizes immune checkpoint blockade response to elicit systemic antitumor immunity against intraocular melanoma and its metastasis.
Kim S; Kim SA; Nam GH; Hong Y; Kim GB; Choi Y; Lee S; Cho Y; Kwon M; Jeong C; Kim S; Kim IS
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479026
[TBL] [Abstract][Full Text] [Related]
12. Mitochondria-Targeting Immunogenic Cell Death Inducer Improves the Adoptive T-Cell Therapy Against Solid Tumor.
Jiang Q; Zhang C; Wang H; Peng T; Zhang L; Wang Y; Han W; Shi C
Front Oncol; 2019; 9():1196. PubMed ID: 31781498
[TBL] [Abstract][Full Text] [Related]
13. Phase I Trial of Intratumoral Injection of
Lee JM; Lee MH; Garon E; Goldman JW; Salehi-Rad R; Baratelli FE; Schaue D; Wang G; Rosen F; Yanagawa J; Walser TC; Lin Y; Park SJ; Adams S; Marincola FM; Tumeh PC; Abtin F; Suh R; Reckamp KL; Lee G; Wallace WD; Lee S; Zeng G; Elashoff DA; Sharma S; Dubinett SM
Clin Cancer Res; 2017 Aug; 23(16):4556-4568. PubMed ID: 28468947
[No Abstract] [Full Text] [Related]
14. Effective cancer immunotherapy by natural mouse conventional type-1 dendritic cells bearing dead tumor antigen.
Wculek SK; Amores-Iniesta J; Conde-Garrosa R; Khouili SC; Melero I; Sancho D
J Immunother Cancer; 2019 Apr; 7(1):100. PubMed ID: 30961656
[TBL] [Abstract][Full Text] [Related]
15. Raddeanin A Enhances Mitochondrial DNA-cGAS/STING Axis-Mediated Antitumor Immunity by Targeting Transactive Responsive DNA-Binding Protein 43.
Yin M; Dong J; Sun C; Liu X; Liu Z; Liu L; Kuang Z; Zhang N; Xiao D; Zhou X; Deng H
Adv Sci (Weinh); 2023 May; 10(13):e2206737. PubMed ID: 36876644
[TBL] [Abstract][Full Text] [Related]
16. Heterologous prime-boost vaccination targeting MAGE-type antigens promotes tumor T-cell infiltration and improves checkpoint blockade therapy.
McAuliffe J; Chan HF; Noblecourt L; Ramirez-Valdez RA; Pereira-Almeida V; Zhou Y; Pollock E; Cappuccini F; Redchenko I; Hill AV; Leung CSK; Van den Eynde BJ
J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34479921
[TBL] [Abstract][Full Text] [Related]
17. Intratumoral immunotherapy using a TLR2/3 agonist, L-pampo, induces robust antitumor immune responses and enhances immune checkpoint blockade.
Lee WS; Kim DS; Kim JH; Heo Y; Yang H; Go EJ; Kim JH; Lee SJ; Ahn BC; Yum JS; Chon HJ; Kim C
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35764365
[TBL] [Abstract][Full Text] [Related]
18. Red blood cell-based vaccines for ameliorating cancer chemoimmunotherapy.
Su L; Hao Y; Li R; Pan W; Ma X; Weng J; Min Y
Acta Biomater; 2022 Dec; 154():401-411. PubMed ID: 36241013
[TBL] [Abstract][Full Text] [Related]
19. Engineered exosomes as an in situ DC-primed vaccine to boost antitumor immunity in breast cancer.
Huang L; Rong Y; Tang X; Yi K; Qi P; Hou J; Liu W; He Y; Gao X; Yuan C; Wang F
Mol Cancer; 2022 Feb; 21(1):45. PubMed ID: 35148751
[TBL] [Abstract][Full Text] [Related]
20. PD-L1/TLR7 dual-targeting nanobody-drug conjugate mediates potent tumor regression via elevating tumor immunogenicity in a host-expressed PD-L1 bias-dependent way.
Yu X; Long Y; Chen B; Tong Y; Shan M; Jia X; Hu C; Liu M; Zhou J; Tang F; Lu H; Chen R; Xu P; Huang W; Ren J; Wan Y; Sun J; Li J; Jin G; Gong L
J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36253000
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]